CFHR2抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human urinary bladder tissue lysate, Primary antibody: P02504(CFHR2 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02504(CFHR2 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P02504(CFHR2 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

**Background of CFHR2 Antibody**

The Complement Factor H-Related Protein 2 (CFHR2) is a member of the complement factor H (CFH) protein family, which plays a critical role in regulating the alternative pathway of the complement system. CFHR2 shares structural homology with CFH, a key inhibitor of complement activation, but exhibits distinct functional properties. It is encoded by the *CFHR2* gene located within the complement factor H-related gene cluster on chromosome 1q32.

CFHR2 is involved in modulating immune responses, particularly by interacting with C3b, C3d, and glycosaminoglycans, though its precise regulatory mechanisms remain less defined compared to CFH. Studies suggest CFHR2 may compete with CFH for binding sites on cell surfaces, influencing complement-mediated inflammation and tissue homeostasis. Dysregulation of CFHR2 has been implicated in diseases linked to complement overactivation, such as atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), and autoimmune disorders.

Antibodies targeting CFHR2 are essential tools for investigating its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to study CFHR2 in biological samples. Additionally, CFHR2 antibodies aid in exploring its role in disease pathogenesis, particularly in conditions associated with genetic variants (e.g., *CFHR2* deletions or polymorphisms) that alter complement regulation. Research utilizing these antibodies continues to clarify CFHR2's interplay with other complement proteins and its potential as a therapeutic target.